ASH1L and hepatocellular carcinoma: Based on drug sensitivity data, we identified treatment combinations that selectively target HCC subtypes with E2F1-ASH1L-AS1/APPLE-ERK1/2 axis hyperactivation, offering a rationale for precision therapy in this molecular context (Fig. 9).